Eli Lilly: Will A New Rival Hobble Its Top Growth Driver?
August 17, 2017 at 12:17 PM EDT
A rival diabetes drug bested Eli Lilly's top growth driver in a recent clinical trial. What does this mean for the U.S. pharmaceutical giant.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|